Welcome to our dedicated page for Climb Bio news (Ticker: CLYM), a resource for investors and traders seeking the latest updates and insights on Climb Bio stock.
Climb Bio, Inc. (Nasdaq: CLYM) is a clinical-stage biotechnology company advancing novel therapies for immune-mediated diseases. This page aggregates official announcements, clinical trial updates, and strategic developments related to their pipeline of monoclonal antibody therapies.
Investors and researchers will find timely updates on budoprutug (anti-CD19) and CLYM116 (anti-APRIL) programs targeting B-cell-mediated conditions including primary membranous nephropathy and IgA nephropathy. The repository includes regulatory filings, partnership announcements, and scientific presentation summaries.
All content undergoes strict verification to ensure accuracy of clinical data interpretations and corporate developments. Bookmark this page for direct access to material news affecting CLYM's therapeutic pipeline and market position within the immunology sector.
Climb Bio (NASDAQ: CLYM) reported Q3 2025 results and clinical progress on Nov 6, 2025. The company held $175.8 million in cash, cash equivalents and marketable securities as of Sept 30, 2025, which management expects will fund operations through 2027. Key clinical programs advanced: the PrisMN Phase 2 trial in primary membranous nephropathy has been initiated; a subcutaneous Phase 1 for budoprutug is enrolling with initial data expected H1 2026; ITP and SLE Phase 1b/2a trials expect initial data H2 2026. CLYM116 received regulatory clearance for Phase 1 dosing, with first subject anticipated by year-end 2025 and initial data mid-2026. Q3 operating items: R&D $9.1M, G&A $5.8M, other income $2.0M.
Leadership strengthened with appointments including Susan Altschuller, Ph.D., MBA as CFO.
Climb Bio (Nasdaq: CLYM) announced that executives will participate in three investor conferences in November–December 2025: Guggenheim's 2nd Annual Healthcare Innovation Conference in Boston on Nov 10, 2025 at 11:30 a.m. ET, Baird Biotech Discovery Series (virtual) on Nov 18, 2025 at 1:30 p.m. ET, and Piper Sandler’s 37th Annual Healthcare Conference in New York on Dec 2, 2025 at 9:30 a.m. ET.
Each appearance will include fireside chats; select events include one-on-one investor meetings. Live webcasts and replay recordings will be available via the Investors & Media section of the Climb Bio website and will be archived for at least 30 days.
Climb Bio (Nasdaq: CLYM) announced two senior hires on Oct 21, 2025: Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy. The appointments aim to support execution of clinical development for budoprutug and CLYM116 and to improve operational and workforce capabilities.
Climb Bio granted inducement equity awards on Oct 20, 2025: non-statutory stock options to acquire an aggregate of 360,000 shares, exercise price $2.32 (Nasdaq close on Oct 20, 2025), ten-year term, vesting over four years (25% after one year, then monthly over 36 months).
Climb Bio (Nasdaq: CLYM) will present preclinical and clinical data at ASN Kidney Week 2025 in Houston, Nov 6-9, 2025.
CLYM116: preclinical data show the Fc-engineered anti-APRIL mAb promoted APRIL degradation, enhanced antibody recycling and produced deep, durable IgA reduction in models, supporting development for IgA nephropathy (IgAN). Presentation: Poster SA-PO0253 on Nov 8, 2025, 10:00 AM–12:00 PM.
Budoprutug: published Phase 1b long-term follow-up (NCT04652570) in primary membranous nephropathy reported proteinuria control up to 3 years after up to four doses in four patients; three required no further immunosuppression and no clinically significant treatment-related adverse events were observed. Abstracts available on the ASN Kidney Week website.
Climb Bio (NASDAQ:CLYM), a clinical-stage biotechnology company, has appointed Susan Altschuller, Ph.D., MBA as Chief Financial Officer. Dr. Altschuller brings over 20 years of strategic and financial leadership experience, notably serving as CFO of Cerevel Therapeutics until its $8.7B AbbVie acquisition and as CFO of ImmunoGen.
As part of her appointment, Dr. Altschuller received an inducement equity award of 600,000 stock options with a ten-year term, vesting over four years. The company is advancing two key programs, budoprutug and CLYM116, with significant clinical data expected in the coming year.
Climb Bio (NASDAQ:CLYM) has announced promising preclinical data for CLYM116, its novel therapeutic candidate for IgA nephropathy (IgAN). The study demonstrated superior performance compared to first-generation anti-APRIL monoclonal antibody sibeprenlimab, showing a 2-3 times longer half-life and deeper IgA reduction of >70%.
The company plans to initiate Phase 1 trials in Q4 2025, with initial data expected by mid-2026. CLYM116's subcutaneous formulation showed 85% bioavailability with favorable tolerability. The market opportunity is significant, estimated at $10-20 billion in the US alone, with approximately 170,000 patients.
Climb Bio (Nasdaq: CLYM) announced a webcast event scheduled for September 29, 2025, at 8:00 a.m. ET to discuss their CLYM116 program and IgA Nephropathy (IgAN) opportunity. The event will feature renowned nephrologist Dr. Craig E. Gordon alongside the company's management team.
CLYM116, a preclinical-stage monoclonal antibody, targets APRIL protein using a unique 'sweeper' mechanism. This approach may offer best-in-class efficacy with reduced dosing frequency. The company plans to file an IND or CTA for CLYM116 in H2 2025.
The webcast will cover IgAN market opportunities, comparative preclinical data, and development strategies. It will be available through Climb Bio's investor relations website.
Climb Bio (Nasdaq: CLYM), a clinical-stage biotechnology company focused on immune-mediated disease therapeutics, has announced its participation in four major investor conferences in September 2025.
The company will participate in the Cantor Global Healthcare Conference (Sept 5), Baird Global Healthcare Conference (Sept 9), Morgan Stanley Annual Global Healthcare Conference (Sept 10), and Stifel Virtual Immunology and Inflammation Forum (Sept 16). Most events will feature fireside chats or presentations along with one-on-one investor meetings.
Live webcasts will be available through Climb Bio's investor relations website, with replays accessible for 30 days after each event.
Climb Bio (Nasdaq: CLYM), a clinical-stage biotechnology company focused on immune-mediated disease therapeutics, has announced its participation in four major investor conferences in September 2025.
The company will participate in the Cantor Global Healthcare Conference (Sept 5), Baird Global Healthcare Conference (Sept 9), Morgan Stanley Annual Global Healthcare Conference (Sept 10), and Stifel Virtual Immunology and Inflammation Forum (Sept 10). Most events will feature fireside chats or presentations along with one-on-one investor meetings.
Live webcasts will be available through Climb Bio's investor relations website, with replays accessible for 30 days after each event.
Climb Bio (Nasdaq: CLYM) reported Q2 2025 financial results and provided significant pipeline updates. The company has advanced its two key programs: budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL antibody.
Key developments include: First patients dosed in both ITP and SLE trials for budoprutug, upcoming initiation of pMN Phase 2 trial, development of a subcutaneous formulation with promising non-clinical data, and advancement of CLYM116 toward clinical development for IgAN. The company appointed Edgar D. Charles, M.D. as Chief Medical Officer.
Financial highlights: $187.4 million in cash and equivalents as of June 30, 2025, with runway through 2027. R&D expenses increased to $6.6 million from $1.0 million year-over-year, while G&A expenses were $4.1 million.
FAQ
What is the current stock price of Climb Bio (CLYM)?
What is the market cap of Climb Bio (CLYM)?
